Ehave, Inc. Announces its KetaDASH Mobile Unit Delivered to Miami Beach.
MIAMI, June 03, 2022 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
Revive Therapeutics (RVVTF, RVV): Updates and News Archive.
Recent Headlines
(See FDA Filing Submission at Bottom)
LIVE QUOTE
Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs
Ehave’s Mobile Ketamine Clinic, Rolling into Town.
Longer term, Ehave's (EHVVF) performance has been a quite a disappointment. Investors grew impatient for the launch...
Coming This Monday..
Microdose's Wonderland: Miami Conference to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November...
Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
Not wanting to be caught...
Ehave (EHVVF) Announces Inclusion in the 2021 Psychedelic Investor Guide
MIAMI, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic...
MindMed (MNMD) IPO on Nasdaq: Becomes Second Public Psychedelic Company.
InvestmentU
By Amber Deter
Apr 27, 2021 at 12:55PM
The MindMed IPO is making...
Latest article
Iconic Brands (ICNB) Reports Revenues of $13.8 Million vs $4 Million. Bounces 40% Intraday.
After a Rough Six Months in the market, Nine Month Numbers Propels the Stock 40% Higher Signaling Possible Bottoming Process. ...
Adding Silo Pharma (SILO) $3.50 to Watch List.
Look What We Found!
We launched the Psychedelic Stock Review a little more than a year ago and decided...
Alzheimer Drug Trials
A winner is crowned in head-to-head Alzheimer's battle between Biogen's Aduhelm and Lilly - Dec 1, 2022
Eli...
